NCT03216538View on ClinicalTrials.gov

Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 8, 2018

Primary Completion Date

May 1, 2020

Study Completion Date

July 1, 2020

Conditions
Neovascular Age-related Macular Degeneration
Interventions
DRUG

AS101 1% oral solution

0.4 ml daily p.o.

DRUG

Placebo

0.4 ml daily p.o.

Trial Locations (1)

Unknown

Meir MC, Kfar Saba

Sponsors

Lead Sponsor

Feramda
All Listed Sponsors
lead

Feramda

INDUSTRY